Company / Capital Expenditures
PALVELLA THERAPEUTICS, INC. Capital Expenditures History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$171.0K
FY2023
5-year range
$171.0K / $2.7M
FY2019-FY2023
Trend
-83.6%
vs FY2022
Sector context
#161 of 194
Health Care
What the data says
PALVELLA THERAPEUTICS, INC.'s capital expenditures of $171,000 is lower than 83% of companies in the Health Care sector (FY2023). Declined from $3M to $171,000 over the past 2 years.
Based on SEC 10-K filings.
$171,000 in FY2023 with a 5-year CAGR of -38.5%.
Declined from $3M to $171,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -58.9%
- 5-Year CAGR
- -38.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 194This company $171.0K Sector average $117.5M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -38.5%, indicating a declining trend.
- In FY2023, capital expenditures decreased 83.6% year-over-year.
- Ranks #161 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- Strong profit margin: 43.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $171.0K | -83.6% |
| FY2022 | $1.0M | -61.8% |
| FY2021 | $2.7M | +10.7% |
| FY2020 | $2.5M | +0.0% |
| FY2019 | $2.5M | +26.3% |
| FY2018 | $1.9M | +248.2% |
| FY2017 | $560.0K | +0.0% |
| FY2016 | $560.0K | -9.8% |
| FY2015 | $620.7K | +132.1% |
As of FY2023 · SEC 10-K Annual Filings · Updated Jun 30, 2026